YORVIPATH pregnancy and breastfeeding safety study
Part of Hormones & metabolism clinical trials.
This study tracks the health of mothers and babies who were exposed to YORVIPATH (a medicine for hypoparathyroidism) around the time of pregnancy or while breastfeeding. It aims to understand if the medicine affects pregnancy outcomes or infant health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 15 and 50 years old.
- You took YORVIPATH within 15 days before getting pregnant or at any time during pregnancy.
- You agree to share your medical information and sign a consent form (or your parent/guardian does if you are a minor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures how much of the medicine YORVIPATH (palopegteriparatide) gets into breast milk. It helps mothers who need this medicine and want to breastfeed understand if it is safe for their baby.
This study tests a new medicine called palopegteriparatide for teenagers with long-term hypoparathyroidism (low parathyroid hormone). The medicine is given as a daily injection and aims to help control calcium levels.
This trial is for adults with hypoparathyroidism who are already taking a drug called palopegteriparatide (TransCon PTH) at a certain dose. It tests whether higher doses of this drug can better control calcium levels and reduce the need for other supplements.
This trial tests a new medicine called EXT608 for adults with hypoparathyroidism. It aims to see if this medicine can help manage calcium levels better than current treatments.
This trial tests an investigational drug called XH02 for people with hypoparathyroidism (low parathyroid hormone) that is not well controlled with standard calcium and vitamin D treatments. The goal is to see if XH02 is safe and effective at managing symptoms.
This trial tests an experimental drug called Canvuparatide against a placebo to see if it can help adults with a condition called hypoparathyroidism, where the body doesn't make enough parathyroid hormone. The goal is to improve calcium levels and reduce the need for high-dose calcium and vitamin D supplements.
Hear when a new Hypoparathyroidism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.